AstraZeneca announces positive results from phase 3 trial for Tagrisso plus chemotherapy
Betsy Goodfellow | May 17, 2023 | News story | Research and Development | AstraZeneca, Cancer, Oncology, Tagrisso, chemotherapy
AstraZeneca has announced positive results from the FLAURA2 phase 3 trial which showed that Tagrisso (osimertinib), in combination with chemotherapy, demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) when compared to Tagrisso alone in the treatment of patients with locally advanced (stage IIIB-IIIC) or metastatic (stage IV) epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC).
The drug’s safety results and discontinuation rates due to adverse events remained consistent with previously established profiles of the medicine.
Full data from the trial is expected to be presented at a forthcoming medical meeting, after which it will be shared with global health authorities.
Pasi A Jänne, MD PhD, medical oncologist at Dana-Farber Cancer Institute and principal investigator for the FLAURA2 trial, commented: “As the global standard of care for EGFR-mutated non-small cell lung cancer, osimertinib monotherapy has transformed the treatment landscape allowing many patients the opportunity to achieve improved survival. FLAURA2 provides compelling evidence that the addition of chemotherapy to osimertinib can provide a new option for patients and clinicians that further improves outcomes compared to osimertinib alone and as such, can further delay treatment resistance and disease progression.”
Susan Galbraith, executive vice president of Oncology R&D at AstraZeneca, added: “These significant FLAURA2 results show Tagrisso has the potential to offer patients in the first-line setting a new treatment option that can extend the time they live without their disease progressing. This meaningfully builds on successive trials which have demonstrated improved clinical benefit with Tagrisso in patients with EGFR-mutated lung cancer.”
Betsy Goodfellow
Related Content
AI in pharma: From lab development to patient impact
In the decade to 2025, AI use in vaccine development has increased markedly but is …
NICE recommends Benralizumab for Rare Form of Vasculitis
The National Institute for Health and Care Excellence (NICE) has recommended AstraZeneca’s benralizumab (Fasenra) as …
Central nervous system cancer metastases – the evolution of diagnostics and treatment
The current forms of immunotherapy, how T cell therapy works and what the future holds
